ONTOLOGY REPORT - ANNOTATIONS
abnormal acute inflammation
|
| S |
Hsd:SD |
Sprague Dawley |
|
Induced |
IED |
|
|
|
RGD:6903837 |
RGD |
abnormal acute phase protein level
|
| Q |
Apr1 |
Acute phase response QTL 1 |
|
|
QTM |
12 |
20,418,353 |
46,782,294 |
RGD:629561 |
RGD |
| Q |
Apr2 |
Acute phase response QTL 2 |
|
|
QTM |
5 |
142,573,432 |
173,096,209 |
RGD:629561 |
RGD |
| Q |
Apr4 |
Acute phase response QTL 4 |
|
|
QTM |
12 |
2,248,421 |
46,782,294 |
RGD:629561 |
RGD |
abnormal CD8-positive T cell morphology
|
| Q |
Cdexp1 |
CD45RC expression in CD8 T cells QTL 1 |
|
|
IAGP |
9 |
1 |
26,311,568 |
RGD:1302824 |
RGD |
| Q |
Cdexp2 |
CD45RC expression in CD8 T cells QTL 2 |
|
|
IAGP |
20 |
3,660,638 |
10,410,227 |
RGD:1302824 |
RGD |
abnormal circulating interleukin-6 level
|
| Q |
Apr3 |
Acute phase response QTL 3 |
|
|
IED |
10 |
16,579,339 |
61,579,339 |
RGD:629561 |
RGD |
| Q |
Apr5 |
Acute phase response QTL 5 |
|
|
IED |
12 |
568,621 |
45,568,621 |
RGD:629561 |
RGD |
| Q |
Apr6 |
Acute phase response QTL 6 |
|
|
IED |
14 |
1 |
42,665,455 |
RGD:629561 |
RGD |
abnormal circulating serum amyloid protein level
|
| S |
F344-Tg(APPswe)Opaz |
|
|
|
IED |
|
|
|
RGD:2292518 |
RGD |
abnormal inflammatory response
|
| Q |
Cari1 |
Carrageenan-induced inflammation QTL 1 |
|
|
QTM |
10 |
55,851,811 |
101,848,470 |
RGD:69693 |
RGD |
| Q |
Cari2 |
Carrageenan-induced inflammation QTL 2 |
|
|
QTM |
2 |
146,659,370 |
210,636,169 |
RGD:70860 |
RGD |
| Q |
Eae12 |
Experimental allergic encephalomyelitis QTL 12 |
|
|
QTM |
10 |
96,667,338 |
105,886,241 |
RGD:69695 |
RGD |
| Q |
Eae14 |
Experimental allergic encephalomyelitis QTL 14 |
|
|
QTM |
13 |
24,701,710 |
69,701,710 |
RGD:69695 |
RGD |
| Q |
Eaez |
Experimental allergic encephalomyelitis QTL z |
|
|
QTM |
18 |
13,239,641 |
58,239,641 |
RGD:61031 |
RGD |
| S |
DA/Ztm |
|
|
|
TAS |
|
|
|
RGD:2293859 |
RGD |
| S |
PVG.1AV1 |
Piebald-Viral-Glaxo |
|
|
TAS |
|
|
|
RGD:2293859 |
RGD |
abnormal interferon-gamma secretion
|
| Q |
Ean2 |
Experimental allergic neuritis QTL 2 |
|
|
IED |
4 |
82,700,691 |
96,313,512 |
RGD:2306769 |
RGD |
| Q |
Ean4 |
Experimental allergic neuritis QTL 4 |
|
|
IED |
10 |
87,849,516 |
98,392,508 |
RGD:2306769 |
RGD |
| Q |
Ean5 |
Experimental allergic neuritis QTL 5 |
|
|
IED |
10 |
76,043,832 |
98,392,296 |
RGD:2306769 |
RGD |
abnormal leukocyte cell number
|
| Q |
Cm6 |
Cardiac mass QTL 6 |
|
|
QTM |
7 |
47,145,774 |
107,950,815 |
RGD:727992 |
RGD |
| Q |
Wbc1 |
White blood cell count QTL 1 |
|
|
QTM |
5 |
89,261,341 |
147,065,912 |
RGD:727992 |
RGD |
abnormal level of surface class II molecules
|
| Q |
Neuinf10 |
Neuroinflammation QTL 10 |
|
|
IED |
11 |
31,988,113 |
81,091,531 |
RGD:2311085 |
RGD |
| Q |
Neuinf11 |
Neuroinflammation QTL 11 |
|
|
IED |
3 |
10,829,503 |
75,308,165 |
RGD:2311085 |
RGD |
| Q |
Neuinf12 |
Neuroinflammation QTL 12 |
|
|
IED |
15 |
1 |
61,161,186 |
RGD:2311085 |
RGD |
| Q |
Neuinf2 |
Neuroinflammation QTL 2 |
|
|
IAGP |
10 |
6,172,805 |
6,380,753 |
RGD:1358788 |
RGD |
| Q |
Neuinf3 |
Neuroinflammation QTL 3 |
|
|
IAGP |
10 |
3,219,701 |
5,339,859 |
RGD:1358788 |
RGD |
| Q |
Neuinf4 |
Neuroinflammation QTL 4 |
|
|
IED |
1 |
1 |
41,225,199 |
RGD:2311085 |
RGD |
| Q |
Neuinf5 |
Neuroinflammation QTL 5 |
|
|
IED |
7 |
10,973,606 |
87,034,412 |
RGD:2311085 |
RGD |
| Q |
Neuinf6 |
Neuroinflammation QTL 6 |
|
|
IED |
7 |
1 |
30,339,432 |
RGD:2311085 |
RGD |
| Q |
Neuinf7 |
Neuroinflammation QTL 7 |
|
|
IED |
10 |
65,668,446 |
132,729,388 |
RGD:2311085 |
RGD |
| Q |
Neuinf8 |
Neuroinflammation QTL 8 |
|
|
IED |
1 |
55,083,934 |
154,002,647 |
RGD:2311085 |
RGD |
| Q |
Neuinf9 |
Neuroinflammation QTL 9 |
|
|
IED |
10 |
5,761,138 |
65,668,639 |
RGD:2311085 |
RGD |
abnormal lymphopoiesis
|
| S |
WIN/RhwRrrc |
|
|
|
TAS |
|
|
|
RGD:2292495 |
RGD |
abnormal macrophage morphology
|
| G |
Gfi1 |
growth factor independent 1 transcription repressor |
|
|
IEA |
14 |
2,597,303 |
2,606,681 |
RGD:704404 |
RGD |
abnormal mast cell physiology
|
| G |
Fcer1g |
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide |
|
|
IEA |
13 |
87,119,464 |
87,123,902 |
RGD:704404 |
RGD |
| G |
Gab2 |
GRB2-associated binding protein 2 |
|
|
IEA |
1 |
154,348,777 |
154,544,906 |
RGD:704404 |
RGD |
abnormal mononuclear cell differentiation
|
| S |
BN |
BN |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
abnormal osteoclast differentiation
|
| S |
LEW-tl |
|
|
|
IED |
|
|
|
RGD:619693 |
RGD |
abnormal osteoclast physiology
|
| S |
LEW-tl |
|
|
|
IED |
|
|
|
RGD:619693 |
RGD |
abnormal response to transplant
|
| G |
Lta |
lymphotoxin alpha (TNF superfamily, member 1) |
|
|
IED |
20 |
3,657,842 |
3,659,848 |
RGD:1580413 |
RGD |
| G |
Tnfsf4 |
tumor necrosis factor (ligand) superfamily, member 4 |
|
|
IED |
13 |
77,026,337 |
77,050,223 |
RGD:1580395 |
RGD |
abnormal T cell differentiation
|
| S |
WKAH.LEC-Ptprkthid/Tj |
|
|
|
TAS |
1 |
17,328,563 |
17,752,200 |
RGD:1302502 |
RGD |
abnormal type I hypersensitivity reaction
|
| G |
C5ar1 |
complement component 5a receptor 1 |
|
|
IED |
|
|
|
RGD:70679 |
RGD |
acute pancreas inflammation
|
| G |
Ednra |
endothelin receptor type A |
|
|
IED |
19 |
32,042,366 |
32,108,153 |
RGD:1581841 |
RGD |
altered susceptibility to autoimmune disorder
|
| S |
MAXX |
|
|
|
IED |
|
|
|
RGD:724729 |
RGD |
| S |
MW |
Munich Wistar |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
arthritis
|
| S |
AVN |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
DA.E3-(D14Wox8-D14Rat64)/Rhd |
|
|
|
QTM |
14 |
68,573,958 |
68,574,165 |
RGD:730280 |
RGD |
| S |
DA.E3-(D6Wox5-D6Rat90)/Rhd |
|
|
|
IED |
6 |
117,361,909 |
117,362,003 |
RGD:728382 |
RGD |
| S |
DA.F344-(D10Arb21-D10Arb22) |
|
|
|
TAS |
10 |
14,721,135 |
14,721,325 |
RGD:631168 |
RGD |
| S |
DA.F344-(D10Rat204-D10Arb22)/Arb |
|
|
|
QTM |
10 |
95,695,076 |
95,695,218 |
RGD:629569 |
RGD |
| S |
DA.F344-(D10Rat37-D10Arb22) |
|
|
|
TAS |
10 |
24,006,429 |
24,006,612 |
RGD:631168 |
RGD |
| S |
DA.F344-(D4Arb30-D4Arb4)/Arb |
|
|
|
QTM |
4 |
73,972,453 |
154,937,227 |
RGD:629569 |
RGD |
| S |
DA.F344-(D7Arb5-D7Mit2)/Arb |
|
|
|
QTM |
7 |
98,955,064 |
123,191,874 |
RGD:629569 |
RGD |
| S |
DA.F344-(D8Arb15-D8Arb22)/Arb |
|
|
|
QTM |
8 |
71,843,628 |
124,310,337 |
RGD:629569 |
RGD |
| S |
DA.PVG.1AV1-(D4Mgh17-D4Rat56) |
|
|
|
QTM |
4 |
116,611,031 |
143,663,540 |
RGD:629560 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat155-D4Rat84) |
|
|
|
QTM |
4 |
185,398,415 |
185,398,530 |
RGD:629560 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat155-Spr) |
|
|
|
IED |
4 |
119,365,578 |
119,369,308 |
RGD:629560 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat63-D4Rat203) |
|
|
|
QTM |
4 |
156,442,644 |
161,435,775 |
RGD:629560 |
RGD |
| S |
DA/BklArbN |
|
|
|
TAS |
|
|
|
RGD:1285224 |
RGD |
| S |
DA/ZtmRhd |
|
|
|
TAS |
|
|
|
RGD:631850 |
RGD |
| S |
DXE1/Ztm |
|
|
|
TAS |
|
|
|
RGD:61088 |
RGD |
| S |
DXE2/Ztm |
|
|
|
TAS |
|
|
|
RGD:61088 |
RGD |
| S |
DXE3/Ztm |
|
|
|
TAS |
|
|
|
RGD:61088 |
RGD |
| S |
E3/ZtmRhd |
|
|
|
TAS |
|
|
|
RGD:631850 |
RGD |
| S |
F344.DA-(D20Arb2-D20Arb8)/Arb |
|
|
|
QTM |
20 |
2,790,511 |
2,811,567 |
RGD:629569 |
RGD |
| S |
LEW-Tg(HLA-B*2705m1,B2M)133-1Trg |
|
|
|
QTM |
|
|
|
RGD:731214 |
RGD |
| S |
LEW.1AV1 |
|
|
|
QTM |
|
|
|
RGD:61087 |
RGD |
| S |
LEW.1AV1 |
|
|
|
TAS |
|
|
|
RGD:737659 |
RGD |
| S |
LEW/Ztm |
LEW/Ztm |
|
|
TAS |
|
|
|
RGD:1299867 |
RGD |
athymia
|
| G |
Foxn1 |
forkhead box N1 |
|
|
IAGP |
10 |
64,243,323 |
64,256,847 |
RGD:1300512 |
RGD |
| S |
F344.Cg-Foxn1rnu/Kyo |
|
|
|
TAS |
10 |
64,243,323 |
64,256,847 |
RGD:1302502 |
RGD |
autoimmune response
|
| Q |
Iddm20 |
Insulin dependent diabetes mellitus QTL 20 |
|
|
IAGP |
17 |
19,877,005 |
27,819,082 |
RGD:1358924 |
RGD |
CNS inflammation
|
| Q |
Eae16 |
Experimental allergic encephalomyelitis QTL 16 |
|
|
IED |
8 |
8,294,860 |
115,338,082 |
RGD:629629 |
RGD |
| Q |
Eae17 |
Experimental allergic encephalomyelitis QTL 17 |
|
|
IED |
13 |
28,645,448 |
106,366,082 |
RGD:629629 |
RGD |
| Q |
Eae23 |
Experimental allergic encephalomyelitis QTL 23 |
|
Induced |
IED |
10 |
57,438,568 |
63,167,167 |
RGD:2293859 |
RGD |
| Q |
Eae24 |
Experimental allergic encephalomyelitis QTL 24 |
|
|
IED |
4 |
65,821,936 |
71,729,738 |
RGD:2317591 |
RGD |
| Q |
Eae25 |
Experimental allergic encephalomyelitis QTL 25 |
|
|
IED |
4 |
78,039,509 |
82,266,081 |
RGD:2317591 |
RGD |
| Q |
Eae26 |
Experimental allergic encephalomyelitis QTL 26 |
|
|
IED |
4 |
88,462,327 |
104,416,171 |
RGD:2317591 |
RGD |
| Q |
Eae27 |
Experimental allergic encephalomyelitis QTL 27 |
|
|
IED |
4 |
104,415,992 |
114,074,165 |
RGD:2317591 |
RGD |
| Q |
Eae29 |
Experimental allergic encephalomyelitis QTL 29 |
|
|
IED |
1 |
6,253,932 |
25,271,177 |
RGD:4888518 |
RGD |
| Q |
Eae30 |
Experimental allergic encephalomyelitis QTL 30 |
|
|
IED |
1 |
124,308,081 |
130,290,315 |
RGD:6892695 |
RGD |
| Q |
Eae31 |
Experimental allergic encephalomyelitis QTL 31 |
|
|
IED |
1 |
183,163,129 |
193,070,197 |
RGD:6892695 |
RGD |
| Q |
Eae32 |
Experimental allergic encephalomyelitis QTL 32 |
|
Resistance |
IED |
17 |
33,277,173 |
42,659,723 |
RGD:4889889 |
RGD |
| Q |
Eae33 |
Experimental allergic encephalomyelitis QTL 33 |
|
Resistance |
IED |
17 |
59,104,847 |
66,993,271 |
RGD:4889889 |
RGD |
| Q |
Pia41 |
Pristane induced arthritis QTL 41 |
|
|
IED |
1 |
183,163,129 |
185,328,208 |
RGD:6892695 |
RGD |
| S |
AS |
Albino Surgery |
|
|
IED |
|
|
|
RGD:704436 |
RGD |
| S |
CAR/N |
Hunt-Hoppert caries resistant; CA/R |
|
|
IED |
|
|
|
RGD:632069 |
RGD |
| S |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
|
|
Resistance |
IED |
17 |
27,618,789 |
75,802,944 |
RGD:4889889 |
RGD |
| S |
DA.PVG.1AV1-(D1Rat248-D1Rat10)/Kini |
|
|
Induced |
IED |
1 |
6,253,932 |
25,271,177 |
RGD:4888518 |
RGD |
| S |
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini |
|
|
Severity |
IED |
4 |
79,604,076 |
104,416,171 |
RGD:2317591 |
RGD |
| S |
DA.PVG.1AV1-(D4Got64)/Kini |
|
|
|
IED |
4 |
80,856,738 |
80,856,941 |
RGD:2317591 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini |
|
|
|
IED |
4 |
82,700,691 |
104,416,171 |
RGD:2317591 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini |
|
|
|
IED |
4 |
58,550,170 |
104,416,171 |
RGD:2317591 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini |
|
|
Resistance |
IED |
4 |
58,550,170 |
82,090,355 |
RGD:2317591 |
RGD |
| S |
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini |
|
|
|
IED |
4 |
88,462,327 |
104,416,171 |
RGD:2317591 |
RGD |
| S |
Kini:DA,PVG-G10 |
|
|
Induced |
IED |
|
|
|
RGD:2293859 |
RGD |
| S |
PVG.LEW-(D1Rat270-D1Rat68)/Kini |
|
|
|
IED |
1 |
130,290,073 |
193,070,197 |
RGD:6892695 |
RGD |
colitis
|
| S |
LEW-Tg(HLA-B*2705m1,B2M)133-1Trg |
|
|
|
QTM |
|
|
|
RGD:731214 |
RGD |
decreased leukocyte cell number
|
| Q |
Wbc3 |
White blood cell count QTL 3 |
|
Induced |
IED |
5 |
112,840,801 |
157,840,801 |
RGD:2316974 |
RGD |
| Q |
Wbc4 |
White blood cell count QTL 4 |
|
Induced |
IED |
7 |
1 |
36,741,943 |
RGD:2316974 |
RGD |
| Q |
Wbc5 |
White blood cell count QTL 5 |
|
Induced |
IED |
8 |
10,116,155 |
55,116,155 |
RGD:2316974 |
RGD |
| S |
BBDP.WF-(D8Rat59-D8Sunn1467)/Sunn |
|
|
|
IED |
8 |
112,242,639 |
128,970,675 |
RGD:1624306 |
RGD |
decreased lymphocyte cell number
|
| S |
BB/N |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
BBDP/Hri |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
BBDP/Rhw |
|
|
|
QTM |
|
|
|
RGD:61480 |
RGD |
| S |
BBDR.BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
TAS |
4 |
75,808,584 |
77,809,321 |
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Arb11-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Got33-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Got59-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/1Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/2Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/3Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat153-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat153-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat253-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat253-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat26-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat27-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBZ |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
BDIX |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
LEW.Cg-Foxn1rnu/NRrrc |
|
|
|
TAS |
|
|
|
RGD:2292495 |
RGD |
decreased mast cell number
|
| G |
Hdc |
histidine decarboxylase |
|
|
IEA |
3 |
114,119,316 |
114,138,107 |
RGD:704404 |
RGD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
|
IAGP |
14 |
34,906,043 |
34,984,819 |
RGD:5133424 |
RGD |
decreased neutrophil cell number
|
| G |
Gfi1 |
growth factor independent 1 transcription repressor |
|
|
IEA |
14 |
2,597,303 |
2,606,681 |
RGD:704404 |
RGD |
decreased Peyer's patch number
|
| S |
LEW.Cg-Foxn1rnu/NRrrc |
|
|
|
TAS |
|
|
|
RGD:2292495 |
RGD |
decreased susceptibility to autoimmune diabetes
|
| Q |
Iddm38 |
Insulin dependent diabetes mellitus QTL 38 |
|
|
IED |
4 |
66,220,947 |
69,183,485 |
RGD:2306526 |
RGD |
| Q |
Iddm39 |
Insulin dependent diabetes mellitus QTL 39 |
|
|
IED |
4 |
76,492,967 |
76,829,366 |
RGD:2306526 |
RGD |
| S |
ACI.BBDP-(RT1u),(Gimap5)/Sunn |
|
|
|
IED |
|
|
|
RGD:2293011 |
RGD |
| S |
BBDR.F344-(D4Arb11-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Got33-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Got59-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/1Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/2Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat102-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/3Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat153-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat153-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat153-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
TAS |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat253-D4Rat27),BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat253-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat26-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR.F344-(D4Rat27-D4Rhw8),BBDP-(D4Rhw6-D4Rat62)/Rhw |
|
|
|
IED |
|
|
|
RGD:2306526 |
RGD |
| S |
BBDR/RhwRrrc |
|
|
|
TAS |
|
|
|
RGD:2292495 |
RGD |
| S |
BBDR/WorBrm |
|
|
|
TAS |
|
|
|
RGD:1624306 |
RGD |
| S |
WF.BBDR-(Clcn1-D4Rat228)/Wor |
|
|
Resistance |
IED |
4 |
70,052,319 |
70,081,449 |
RGD:1600776 |
RGD |
| S |
WF.BBDR-(D4Got48-D4Got43)/Wor |
|
|
Resistance |
IED |
4 |
65,628,995 |
68,036,772 |
RGD:1600776 |
RGD |
| S |
WIN/RhwRrrc |
|
|
|
TAS |
|
|
|
RGD:2292495 |
RGD |
decreased susceptibility to experimental autoimmune myasthenia gravis
|
| G |
C6 |
complement component 6 |
|
|
IAGP |
2 |
53,691,290 |
53,764,539 |
RGD:1600670 |
RGD |
decreased susceptibility to experimental autoimmune uveoretinitis
|
| Q |
Eau5 |
Experimental allergic uveoretinitis QTL 5 |
|
|
IED |
2 |
210,636,008 |
247,306,073 |
RGD:2296064 |
RGD |
| Q |
Eau6 |
Experimental allergic uveoretinitis QTL 6 |
|
|
IED |
7 |
90,478,161 |
135,478,161 |
RGD:2296064 |
RGD |
| Q |
Eau7 |
Experimental allergic uveoretinitis QTL 7 |
|
|
IED |
10 |
35,713,561 |
36,254,741 |
RGD:2296064 |
RGD |
| Q |
Eau8 |
Experimental allergic uveoretinitis QTL 8 |
|
|
IED |
19 |
19,112,825 |
59,218,465 |
RGD:2296064 |
RGD |
| Q |
Eau9 |
Experimental allergic uveoretinitis QTL 9 |
|
|
IED |
10 |
69,160,380 |
86,317,054 |
RGD:2296064 |
RGD |
| S |
F344/NHsd |
F344/NHsd |
|
Resistance |
IED |
|
|
|
RGD:2293749 |
RGD |
decreased susceptibility to induced arthritis
|
| S |
DA.ACI-(D12Wox12-D12Rat53)/Arb |
|
|
|
IED |
12 |
20,932,555 |
43,863,270 |
RGD:1600250 |
RGD |
| S |
DA.ACI-(D2Mit12-D2Mgh29)/Nsi |
|
|
|
IED |
2 |
174,730,375 |
227,310,008 |
RGD:1358860 |
RGD |
| S |
DA.E3-(D12Got46-D12Rat26)/Rhd |
|
|
|
IDA |
12 |
23,362,298 |
23,845,733 |
RGD:1625013 |
RGD |
| S |
DA.E3-(D4Mit16-D4Mgh11)/Rhd |
|
|
|
IED |
4 |
130,228,504 |
171,204,531 |
RGD:631850 |
RGD |
| S |
E3 |
|
|
|
TAS |
|
|
|
RGD:61088 |
RGD |
| S |
E3.DA-(D12Wox5-D12Rat26)/Rhd |
|
|
Induced |
IED |
12 |
23,845,554 |
23,845,733 |
RGD:2306838 |
RGD |
| S |
E3.DA-(D4Wox22-D4Got132)(D12Wox5-D12Rat26)/Rhd |
|
|
Induced |
IED |
|
|
|
RGD:2306838 |
RGD |
| S |
E3/ZtmRhd |
|
|
|
IED |
|
|
|
RGD:2302026 |
RGD |
decreased susceptibility to induced joint inflammation
|
| G |
Bdkrb1 |
bradykinin receptor B1 |
|
|
IED |
6 |
129,760,129 |
129,762,545 |
RGD:1625760 |
RGD |
| Q |
Pia21 |
Pristane induced arthritis QTL 21 |
|
|
IED |
20 |
3,660,646 |
4,740,814 |
RGD:631850 |
RGD |
| Q |
Pia40 |
Pristane induced arthritis QTL 40 |
|
Induced |
IED |
20 |
1,616,449 |
5,447,380 |
RGD:2306838 |
RGD |
| S |
DA.E3-(D12Got46-D12Rat26)/Rhd |
|
|
|
IDA |
12 |
23,362,298 |
23,845,733 |
RGD:1625013 |
RGD |
| S |
E3.DA-(D12Wox5-D12Rat26)/Rhd |
|
|
Induced |
IED |
12 |
23,845,554 |
23,845,733 |
RGD:2306838 |
RGD |
decreased susceptibility to parasitic infection
|
| Q |
Toxo1 |
Toxoplasma gondii resistance QTL 1 |
|
|
IAGP |
10 |
54,220,109 |
61,798,393 |
RGD:1578521 |
RGD |
| Q |
Tspe1 |
Trichinella spiralis expulsion QTL 1 |
|
|
IAGP |
9 |
58,516,719 |
62,957,638 |
RGD:1578305 |
RGD |
| S |
BN.LEW-(D10Mco17-D10Mco14)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
45,106,380 |
RGD:1578521 |
RGD |
| S |
BN.LEW-(D10Mco17-D10Rat116)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
54,220,239 |
RGD:1578521 |
RGD |
| S |
BN.LEW-(D10Mco17-D10Rat31)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
53,616,369 |
RGD:1578521 |
RGD |
| S |
BN.LEW-(D10Mit2-D10Rat221)/Ciml |
|
|
|
IAGP |
10 |
64,860,949 |
64,861,137 |
RGD:1578521 |
RGD |
| S |
DA/Slc |
dark agouti |
|
|
IAGP |
|
|
|
RGD:1578305 |
RGD |
| S |
LEW.BN-(D10Mco17-D10Mco14)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
45,106,380 |
RGD:1578521 |
RGD |
decreased susceptibility to viral infection
|
| S |
BN |
BN |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
PVG |
PVG |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
decreased thymus weight
|
| S |
SS-Rag1em2Mcwi |
|
|
|
IED |
|
|
|
RGD:7207429 |
RGD |
enlarged mesenteric lymph nodes
|
| S |
BN.MES-Cyba/Sna |
|
|
|
IED |
|
|
|
RGD:5134976 |
RGD |
enlarged spleen
|
| G |
Hbb |
hemoglobin, beta |
|
|
IEA |
1 |
161,618,782 |
161,620,193 |
RGD:704404 |
RGD |
enlarged thymus
|
| Q |
Thym3 |
Thymus enlargement QTL 3 |
|
|
QTM |
1 |
141,471,946 |
186,471,946 |
RGD:70859 |
RGD |
| Q |
Thym4 |
Thymus enlargement QTL 4 |
|
|
QTM |
1 |
202,906,624 |
247,906,624 |
RGD:70859 |
RGD |
eye inflammation
|
| Q |
Eau1 |
Experimental allergic uveoretinitis QTL 1 |
|
Induced |
IED |
4 |
69,183,301 |
134,858,710 |
RGD:2296064 |
RGD |
| Q |
Eau2 |
Experimental allergic uveoretinitis QTL 2 |
|
Induced |
IED |
12 |
1 |
29,130,348 |
RGD:2296064 |
RGD |
| Q |
Eau3 |
Experimental allergic uveoretinitis QTL 3 |
|
Induced |
IED |
10 |
35,713,452 |
101,848,683 |
RGD:2296064 |
RGD |
| Q |
Eau4 |
Experimental allergic uveoretinitis QTL 4 |
|
Induced |
IED |
3 |
139,485,124 |
171,063,335 |
RGD:2296064 |
RGD |
| Q |
Eau5 |
Experimental allergic uveoretinitis QTL 5 |
|
Induced |
IED |
2 |
210,636,008 |
247,306,073 |
RGD:2296064 |
RGD |
| Q |
Eau6 |
Experimental allergic uveoretinitis QTL 6 |
|
Induced |
IED |
7 |
90,478,161 |
135,478,161 |
RGD:2296064 |
RGD |
| Q |
Eau7 |
Experimental allergic uveoretinitis QTL 7 |
|
Induced |
IED |
10 |
35,713,561 |
36,254,741 |
RGD:2296064 |
RGD |
| Q |
Eau8 |
Experimental allergic uveoretinitis QTL 8 |
|
Induced |
IED |
19 |
19,112,825 |
59,218,465 |
RGD:2296064 |
RGD |
| Q |
Eau9 |
Experimental allergic uveoretinitis QTL 9 |
|
Induced |
IED |
10 |
69,160,380 |
86,317,054 |
RGD:2296064 |
RGD |
| S |
LEW/NHsd |
|
|
Susceptibility |
IED |
|
|
|
RGD:2296064 |
RGD |
| S |
WKAH/Hok |
Wistar-King Aptekman Hokkaido |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
glomerulonephritis
|
| Q |
Glom15 |
Glomerulus QTL 15 |
|
Susceptibility |
IED |
13 |
78,189,125 |
106,076,220 |
RGD:2293335 |
RGD |
| Q |
Glom16 |
Glomerulus QTL 16 |
|
Susceptibility |
IED |
16 |
819,225 |
49,333,382 |
RGD:2293335 |
RGD |
| Q |
Glom22 |
Glomerulus QTL 22 |
|
|
IDA |
|
|
|
RGD:2293335 |
RGD |
| Q |
Glom23 |
Glomerulus QTL 23 |
|
|
IDA |
2 |
201,223,893 |
254,933,362 |
RGD:2293335 |
RGD |
| Q |
Glom24 |
Glomerulus QTL 24 |
|
|
IDA |
5 |
102,024,381 |
143,540,180 |
RGD:2293335 |
RGD |
| Q |
Glom25 |
Glomerulus QTL 25 |
|
|
IDA |
10 |
86,810,917 |
131,810,917 |
RGD:2293335 |
RGD |
| Q |
Glom26 |
Glomerulus QTL 26 |
|
|
IDA |
15 |
14,072,029 |
71,533,203 |
RGD:2293335 |
RGD |
| Q |
Glom27 |
Glomerulus QTL 27 |
|
|
IED |
13 |
10,556,042 |
106,075,835 |
RGD:7207870 |
RGD |
| S |
BUF/N |
|
|
|
QTM |
|
|
|
RGD:619599 |
RGD |
| S |
FH |
|
|
|
IED |
|
|
|
RGD:724730 |
RGD |
| S |
LEW.WKY-(D13Arb15-D13Rat58)/Tja |
|
|
Resistance |
IED |
13 |
71,116,479 |
96,441,728 |
RGD:7207870 |
RGD |
| S |
LEW.WKY-(D16Rat88-D16Rat40)/Tja |
|
|
Susceptibility |
IED |
16 |
819,225 |
60,432,230 |
RGD:2293336 |
RGD |
| S |
WKY.LEW-(D13Arb10-D13Arb15)(D16Rat88-D16Rat40)/Tja |
|
|
Resistance |
IED |
|
|
|
RGD:2325762 |
RGD |
| S |
WKY.LEW-(D13Arb15-D13Rat58)/Tja |
|
|
Resistance |
IED |
13 |
71,116,479 |
96,441,728 |
RGD:2325762 |
RGD |
| S |
WKY.LEW-(D16Rat88-D16Rat40)/Tja |
|
|
Resistance |
IED |
16 |
819,225 |
60,432,230 |
RGD:2293336 |
RGD |
| S |
WKY/N |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
WKY/NCrl |
|
|
Susceptibility |
IED |
|
|
|
RGD:2293335 |
RGD |
| S |
WKYO/Kyo |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
WN/N |
Inbred Wistar; W/N |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
granulomatous inflammation
|
| Q |
Ginf1 |
Gastrointestinal inflammation QTL 1 |
|
Induced |
IED |
8 |
5,914,098 |
50,914,098 |
RGD:2316974 |
RGD |
| Q |
Ginf2 |
Gastrointestinal inflammation QTL 2 |
|
Induced |
IED |
8 |
5,914,098 |
50,914,098 |
RGD:2316974 |
RGD |
| Q |
Ginf3 |
Gastrointestinal inflammation QTL 3 |
|
Induced |
IED |
17 |
60,979,997 |
97,296,363 |
RGD:2316974 |
RGD |
impaired natural killer cell mediated cytotoxicity
|
| G |
Fcer1g |
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide |
|
|
IEA |
13 |
87,119,464 |
87,123,902 |
RGD:704404 |
RGD |
| Q |
Nka1 |
Natural killer alloreactivity QTL 1 |
|
|
IAGP |
|
|
|
RGD:61084 |
RGD |
increased activated T cell number
|
| Q |
Ean2 |
Experimental allergic neuritis QTL 2 |
|
|
IED |
4 |
82,700,691 |
96,313,512 |
RGD:2306769 |
RGD |
| Q |
Ean4 |
Experimental allergic neuritis QTL 4 |
|
|
IED |
10 |
87,849,516 |
98,392,508 |
RGD:2306769 |
RGD |
| Q |
Ean5 |
Experimental allergic neuritis QTL 5 |
|
|
IED |
10 |
76,043,832 |
98,392,296 |
RGD:2306769 |
RGD |
increased acute inflammation
|
| S |
LEC |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased double-negative T cell number
|
| Q |
Neudeg2 |
Neurodegradation QTL 2 |
|
|
IAGP |
5 |
25,602,274 |
45,822,846 |
RGD:1358788 |
RGD |
| Q |
Neuinf1 |
Neuroinflammation QTL 1 |
|
|
IAGP |
5 |
161,449,395 |
173,096,209 |
RGD:1358788 |
RGD |
increased eosinophil cell number
|
| Q |
Leukc1 |
Leukocyte quantity QTL 1 |
|
|
IED |
19 |
12,235,101 |
57,235,101 |
RGD:5135221 |
RGD |
| Q |
Leukc2 |
Leukocyte quantity QTL 2 |
|
|
IED |
2 |
121,545,310 |
155,102,371 |
RGD:5135221 |
RGD |
| Q |
Leukc3 |
Leukocyte quantity QTL 3 |
|
|
IED |
1 |
223,729,174 |
229,876,997 |
RGD:5135222 |
RGD |
| S |
BN.MES-Cyba/Sna |
|
|
|
IED |
|
|
|
RGD:5134976 |
RGD |
| S |
MES/Slc |
Matsumoto Eosinophilia Shinshu |
|
|
IED |
|
|
|
RGD:5134988 |
RGD |
increased IgE level
|
| Q |
Iresp2 |
Immunoglobin response QTL2 |
|
|
QTM |
10 |
23,428,127 |
32,725,718 |
RGD:619646 |
RGD |
| Q |
Iresp3 |
Immunoglobin response QTL3 |
|
|
QTM |
9 |
2,176,482 |
5,446,654 |
RGD:619646 |
RGD |
| S |
BN/Rj |
|
|
|
QTM |
|
|
|
RGD:619646 |
RGD |
increased IgG level
|
| Q |
Ciaa1 |
CIA Autoantibody QTL 1 |
|
|
QTM |
20 |
2,790,511 |
4,530,895 |
RGD:61062 |
RGD |
| Q |
Ciaa2 |
CIA Autoantibody QTL 2 |
|
|
QTM |
10 |
64,308,668 |
95,695,218 |
RGD:61518 |
RGD |
| Q |
Ciaa3 |
CIA Autoantibody QTL 3 |
|
|
QTM |
9 |
18,347,567 |
63,347,567 |
RGD:61066 |
RGD |
| Q |
Ciaa4 |
CIA Autoantibody QTL 4 |
|
|
QTM |
4 |
128,179,957 |
171,204,531 |
RGD:61067 |
RGD |
| Q |
Ciaa5 |
CIA Autoantibody QTL 5 |
|
|
QTM |
5 |
99,080,786 |
149,757,440 |
RGD:61067 |
RGD |
| Q |
Iresp1 |
Immunoglobin response QTL1 |
|
|
QTM |
20 |
9,301,974 |
13,963,223 |
RGD:619646 |
RGD |
| S |
E3.DA-(D12Wox5-D12Rat26)/Rhd |
|
|
|
IED |
12 |
23,845,554 |
23,845,733 |
RGD:2306838 |
RGD |
| S |
E3.DA-(D4Wox22-D4Got132)(D12Wox5-D12Rat26)/Rhd |
|
|
|
IED |
|
|
|
RGD:2306838 |
RGD |
increased inflammatory response
|
| Q |
Eae15 |
Experimental allergic encephalomyelitis QTL 15 |
|
|
QTM |
18 |
79,585,008 |
80,370,517 |
RGD:69695 |
RGD |
| Q |
Eae2 |
Experimental allergic encephalomyelitis QTL 2 |
|
|
QTM |
4 |
17,617,956 |
36,592,773 |
RGD:69694 |
RGD |
| Q |
Eae3 |
Experimental allergic encephalomyelitis QTL 3 |
|
|
IED |
10 |
27,184,741 |
67,678,060 |
RGD:69694 |
RGD |
| Q |
Eae4 |
Experimental allergic encephalomyelitis QTL 4 |
|
|
QTM |
9 |
1,526,958 |
22,066,101 |
RGD:69712 |
RGD |
| S |
BBDR/Rhw |
|
|
|
QTM |
|
|
|
RGD:61067 |
RGD |
| S |
DA |
DA |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
DA.BN-(D9Wox17-D9Got15)/Kini |
|
|
|
IED |
9 |
1,526,762 |
6,948,180 |
RGD:7241236 |
RGD |
| S |
DA.BN-(D9Wox24-D9Rat44)/Kini |
|
|
Resistance |
IED |
9 |
2,948,882 |
2,949,051 |
RGD:7241236 |
RGD |
| S |
DA.F344-Aia1/4 |
|
|
|
QTM |
10 |
24,006,429 |
24,006,612 |
RGD:625379 |
RGD |
| S |
DA/Bkl |
|
|
|
QTM |
|
|
|
RGD:61066 |
RGD |
| S |
LEW |
Lewis |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc |
|
|
|
QTM |
10 |
101,532,360 |
108,776,963 |
RGD:62404 |
RGD |
| S |
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc |
|
|
|
QTM |
10 |
78,170,416 |
108,776,963 |
RGD:61087 |
RGD |
| S |
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc |
|
|
|
QTM |
10 |
78,170,416 |
91,168,491 |
RGD:62404 |
RGD |
| S |
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc |
|
|
|
QTM |
10 |
91,168,332 |
108,776,963 |
RGD:62404 |
RGD |
| S |
LEW.1F |
|
|
|
QTM |
|
|
|
RGD:631225 |
RGD |
| S |
LEW.BN-(D9Got8-D9Got22)/Kini |
|
|
|
IED |
9 |
3,811,425 |
12,324,010 |
RGD:7241236 |
RGD |
increased leukocyte cell number
|
| Q |
Wbc1 |
White blood cell count QTL 1 |
|
|
IAGP |
5 |
89,261,341 |
147,065,912 |
RGD:727992 |
RGD |
| Q |
Wbc2 |
White blood cell count QTL 2 |
|
|
IAGP |
12 |
25,271,823 |
32,988,661 |
RGD:70849 |
RGD |
| S |
BDIX |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased susceptibility to autoimmune diabetes
|
| S |
BBDP/WorBrm |
|
|
|
TAS |
|
|
|
RGD:1624306 |
RGD |
| S |
BBDR.BBDP-(D4Mit6-D4Mit7)/1Rhw |
|
|
|
IED |
4 |
75,732,943 |
75,733,127 |
RGD:2293508 |
RGD |
| S |
BBDR.BBDP-(D4Mit6-D4Mit7)/2Rhw |
|
|
|
IED |
4 |
75,732,943 |
75,733,127 |
RGD:2293508 |
RGD |
| S |
BBDR.BBDP-(D4Mit6-D4Mit7)/3Rhw |
|
|
|
IED |
4 |
75,732,943 |
75,733,127 |
RGD:2293508 |
RGD |
| S |
BBDR.BBDP-(D4Rhw11-D4Rhw10)/Rhw |
|
|
|
TAS |
4 |
75,808,584 |
77,809,321 |
RGD:2306526 |
RGD |
| S |
F344.ZUC-Leprfa(D14Rat23-D14Rat12)/Tj |
|
|
|
TAS |
14 |
1,764,386 |
41,707,592 |
RGD:1302502 |
RGD |
| S |
F344.ZUC-Leprfa(D7Rat16-D7Mgh20)/Tj |
|
|
|
TAS |
7 |
108,647,236 |
108,647,376 |
RGD:1302502 |
RGD |
| S |
LA/N-cp |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
SD-Tg(Ins2-IAPP)Soel |
|
|
|
IED |
|
|
|
RGD:2313576 |
RGD |
| S |
SD-Tg(Insr-shRNA)14Bdr |
|
|
Model |
IED |
|
|
|
RGD:2307333 |
RGD |
| S |
SD-Tg(Insr-shRNA)29Bdr |
|
|
Model |
IED |
|
|
|
RGD:2307333 |
RGD |
| S |
WF.BBDR-(D4Rat93-D4Rat228)/Wor |
|
|
Susceptibility |
IED |
4 |
67,390,393 |
67,390,598 |
RGD:1600776 |
RGD |
| S |
ZDF |
Vancouver diabetic fatty Zucker |
|
Model |
TAS |
|
|
|
RGD:68929 |
RGD |
increased susceptibility to autoimmune disorder
|
| Q |
Iddm21 |
Insulin dependent diabetes mellitus QTL 21 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| Q |
Iddm22 |
Insulin dependent diabetes mellitus QTL 22 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| Q |
Iddm23 |
Insulin dependent diabetes mellitus QTL 23 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| S |
A28807/N |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
AGUS |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
AS |
Albino Surgery |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
AUG |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
BUF/N |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
CAR/N |
Hunt-Hoppert caries resistant; CA/R |
|
|
IED |
|
|
|
RGD:632069 |
RGD |
| S |
DA |
DA |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
LEJ/Hok |
|
|
|
IED |
|
|
|
RGD:724740 |
RGD |
| S |
LEW.1AR1-iddm/Ztm |
|
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| S |
PVG |
PVG |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
WAG |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased susceptibility to bacterial infection
|
| S |
ODU/N |
Osaka Dental University |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased susceptibility to experimental autoimmune uveoretinitis
|
| Q |
Eau4 |
Experimental allergic uveoretinitis QTL 4 |
|
Induced |
IED |
3 |
139,485,124 |
171,063,335 |
RGD:2296064 |
RGD |
| Q |
Eau5 |
Experimental allergic uveoretinitis QTL 5 |
|
Susceptibility |
IED |
2 |
210,636,008 |
247,306,073 |
RGD:2296064 |
RGD |
| Q |
Eau7 |
Experimental allergic uveoretinitis QTL 7 |
|
Susceptibility |
IED |
10 |
35,713,561 |
36,254,741 |
RGD:2296064 |
RGD |
| Q |
Eau9 |
Experimental allergic uveoretinitis QTL 9 |
|
Susceptibility |
IED |
10 |
69,160,380 |
86,317,054 |
RGD:2296064 |
RGD |
| S |
LEW/NHsd |
|
|
Induced |
IED |
|
|
|
RGD:2296064 |
RGD |
| S |
LEW/SsNHsd |
|
|
Susceptibility |
IED |
|
|
|
RGD:2293749 |
RGD |
increased susceptibility to induced arthritis
|
| G |
Ncf1 |
neutrophil cytosolic factor 1 |
|
|
IAGP |
12 |
23,578,097 |
23,587,292 |
RGD:628543 |
RGD |
| Q |
Pia27 |
Pristane induced arthritis QTL 27 |
|
No_Association |
IED |
11 |
84,560,085 |
85,432,136 |
RGD:2302026 |
RGD |
| Q |
Pia28 |
Pristane induced arthritis QTL 28 |
|
|
IED |
4 |
74,123,346 |
119,123,346 |
RGD:2302026 |
RGD |
| Q |
Pia29 |
Pristane induced arthritis QTL 29 |
|
No_Association |
IED |
16 |
24,934,312 |
69,934,312 |
RGD:2302026 |
RGD |
| Q |
Pia30 |
Pristane induced arthritis QTL 30 |
|
|
IED |
3 |
25,222,506 |
70,222,506 |
RGD:2302026 |
RGD |
| Q |
Pia31 |
Pristane induced arthritis QTL 31 |
|
|
IED |
17 |
1 |
26,143,121 |
RGD:2302026 |
RGD |
| Q |
Pia32 |
Pristane induced arthritis QTL 32 |
|
|
IED |
4 |
107,728,559 |
152,728,559 |
RGD:2302026 |
RGD |
| Q |
Pia33 |
Pristane induced arthritis QTL 33 |
|
|
IED |
5 |
1 |
40,017,184 |
RGD:2302026 |
RGD |
| Q |
Pia34 |
Pristane induced arthritis QTL 34 |
|
|
IED |
|
|
|
RGD:2302026 |
RGD |
| Q |
Pia35 |
Pristane induced arthritis QTL 35 |
|
|
IED |
|
|
|
RGD:2302026 |
RGD |
| Q |
Pia36 |
Pristane induced arthritis QTL 36 |
|
|
IED |
1 |
41,645,883 |
86,645,883 |
RGD:2302026 |
RGD |
| Q |
Pia37 |
Pristane induced arthritis QTL 37 |
|
|
IED |
12 |
14,334,630 |
46,782,294 |
RGD:2302026 |
RGD |
| Q |
Pia38 |
Pristane induced arthritis QTL 38 |
|
Severity |
IED |
12 |
568,621 |
45,568,621 |
RGD:2302026 |
RGD |
| Q |
Pia39 |
Pristane induced arthritis QTL 39 |
|
|
IED |
14 |
10,539,919 |
55,539,919 |
RGD:2302026 |
RGD |
| Q |
Pia41 |
Pristane induced arthritis QTL 41 |
|
|
IED |
1 |
183,163,129 |
185,328,208 |
RGD:6892695 |
RGD |
| S |
DA.E3-(D11Got79-D11Rat50)/Rhd |
|
|
No_Association |
IED |
11 |
82,238,710 |
84,841,212 |
RGD:2302066 |
RGD |
| S |
DA.E3-(D11Got79-D11Wox5)/Rhd |
|
|
No_Association |
IED |
11 |
82,238,710 |
85,432,136 |
RGD:2302066 |
RGD |
| S |
DA/ZtmRhd |
|
|
|
IED |
|
|
|
RGD:2302026 |
RGD |
| S |
LEW.1WR1/WorBrm |
|
|
|
IED |
|
|
|
RGD:2313175 |
RGD |
| S |
PVG.LEW-(D1Rat270-D1Rat68)/Kini |
|
|
|
IED |
1 |
130,290,073 |
193,070,197 |
RGD:6892695 |
RGD |
| S |
Rhd:F344,GK-G21 |
|
|
No_Association |
IED |
|
|
|
RGD:2302066 |
RGD |
increased susceptibility to parasitic infection
|
| S |
BN.LEW-(D10Rat32-D10Rat221)/Ciml |
|
|
|
IAGP |
10 |
53,786,347 |
53,786,515 |
RGD:1578521 |
RGD |
| S |
F344/NSlc |
|
|
|
IAGP |
|
|
|
RGD:1578305 |
RGD |
| S |
LEW.BN-(D10Arb4-D10Rat133)/Ciml |
|
|
|
IAGP |
10 |
46,737,116 |
65,668,639 |
RGD:1578521 |
RGD |
| S |
LEW.BN-(D10Mco17-D10Rat133)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
65,668,639 |
RGD:1578521 |
RGD |
| S |
LEW.BN-(D10Mco17-D10Rat221)/Ciml |
|
|
|
IAGP |
10 |
45,105,978 |
45,106,380 |
RGD:1578521 |
RGD |
| S |
LEW.BN-(D10Mgh7-D10Rat221)/Ciml |
|
|
|
IAGP |
10 |
56,170,962 |
56,171,177 |
RGD:1578521 |
RGD |
| S |
LEW.BN-(D10Rat32-D10Rat133)/Ciml |
|
|
|
IAGP |
10 |
53,786,347 |
65,668,639 |
RGD:1578521 |
RGD |
| S |
LOU/M |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
PVG |
PVG |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased susceptibility to type I hypersensitivity reaction
|
| G |
Fcer1a |
Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide |
|
|
IEA |
13 |
89,429,982 |
89,436,507 |
RGD:704404 |
RGD |
| G |
Fcer1g |
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide |
|
|
IEA |
13 |
87,119,464 |
87,123,902 |
RGD:704404 |
RGD |
increased susceptibility to type II hypersensitivity reaction
|
| Q |
Iresp1 |
Immunoglobin response QTL1 |
|
|
QTM |
20 |
9,301,974 |
13,963,223 |
RGD:619646 |
RGD |
increased susceptibility to viral infection
|
| S |
AO |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
LEW |
Lewis |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
increased T cell number
|
| Q |
Iddm1 |
Insulin dependent diabetes mellitus QTL 1 |
|
|
IED |
|
|
|
RGD:61075 |
RGD |
increased T cell proliferation
|
| Q |
Ean2 |
Experimental allergic neuritis QTL 2 |
|
|
IED |
4 |
82,700,691 |
96,313,512 |
RGD:2306769 |
RGD |
| Q |
Ean4 |
Experimental allergic neuritis QTL 4 |
|
|
IED |
10 |
87,849,516 |
98,392,508 |
RGD:2306769 |
RGD |
| Q |
Ean5 |
Experimental allergic neuritis QTL 5 |
|
|
IED |
10 |
76,043,832 |
98,392,296 |
RGD:2306769 |
RGD |
insulitis
|
| Q |
Iddm11 |
Insulin dependent diabetes mellitus QTL 11 |
|
|
IED |
4 |
56,920,444 |
78,042,833 |
RGD:61480 |
RGD |
| Q |
Iddm24 |
Insulin dependent diabetes mellitus QTL 24 |
|
Not |
IED |
8 |
118,705,293 |
123,876,328 |
RGD:1624306 |
RGD |
| Q |
Iddm37 |
Insulin dependent diabetes mellitus QTL 37 |
|
|
IED |
20 |
1,616,332 |
46,616,332 |
RGD:2313174 |
RGD |
| Q |
Iddm38 |
Insulin dependent diabetes mellitus QTL 38 |
|
Resistance |
IED |
4 |
66,220,947 |
69,183,485 |
RGD:2306526 |
RGD |
| Q |
Iddm39 |
Insulin dependent diabetes mellitus QTL 39 |
|
Resistance |
IED |
4 |
76,492,967 |
76,829,366 |
RGD:2306526 |
RGD |
intestinal inflammation
|
| Q |
Ginf1 |
Gastrointestinal inflammation QTL 1 |
|
Induced |
IED |
8 |
5,914,098 |
50,914,098 |
RGD:2316974 |
RGD |
| Q |
Ginf2 |
Gastrointestinal inflammation QTL 2 |
|
Induced |
IED |
8 |
5,914,098 |
50,914,098 |
RGD:2316974 |
RGD |
| Q |
Ginf3 |
Gastrointestinal inflammation QTL 3 |
|
Induced |
IED |
17 |
60,979,997 |
97,296,363 |
RGD:2316974 |
RGD |
joint inflammation
|
| G |
Fcgrt |
Fc fragment of IgG, receptor, transporter, alpha |
|
|
IEA |
1 |
95,566,717 |
95,575,645 |
RGD:704404 |
RGD |
| Q |
Aia10 |
Adjuvant induced arthritis QTL 10 |
|
Induced |
IED |
15 |
83,677,810 |
109,758,846 |
RGD:2316974 |
RGD |
| Q |
Aia11 |
Adjuvant induced arthritis QTL 11 |
|
Induced |
IED |
17 |
71,569,891 |
77,806,121 |
RGD:2316974 |
RGD |
| Q |
Aia12 |
Adjuvant induced arthritis QTL 12 |
|
Induced |
IED |
17 |
49,069,974 |
94,069,974 |
RGD:2316974 |
RGD |
| Q |
Aia13 |
Adjuvant induced arthritis QTL 13 |
|
Induced |
IED |
2 |
77,630,629 |
79,118,861 |
RGD:2316974 |
RGD |
| Q |
Aia14 |
Adjuvant induced arthritis QTL 14 |
|
Induced |
IED |
|
|
|
RGD:2316974 |
RGD |
| Q |
Aia15 |
Adjuvant induced arthritis QTL 15 |
|
Induced |
IED |
7 |
21,202,126 |
66,202,126 |
RGD:2316974 |
RGD |
| Q |
Aia16 |
Adjuvant induced arthritis QTL 16 |
|
Induced |
IED |
7 |
65,025,373 |
110,025,373 |
RGD:2316974 |
RGD |
| Q |
Aia17 |
Adjuvant induced arthritis QTL 17 |
|
Induced |
IED |
7 |
87,525,274 |
132,525,274 |
RGD:2316974 |
RGD |
| Q |
Aia18 |
Adjuvant induced arthritis QTL 18 |
|
Induced |
IED |
8 |
10,116,155 |
55,116,155 |
RGD:2316974 |
RGD |
| Q |
Aia19 |
Adjuvant induced arthritis QTL 19 |
|
Induced |
IED |
10 |
70,229,781 |
115,229,781 |
RGD:2316974 |
RGD |
| Q |
Aia2 |
Adjuvant induced arthritis QTL 2 |
|
|
QTM |
4 |
36,592,628 |
73,972,591 |
RGD:61035 |
RGD |
| Q |
Aia20 |
Adjuvant induced arthritis QTL 20 |
|
Induced |
IED |
10 |
41,317,054 |
86,317,054 |
RGD:2316974 |
RGD |
| Q |
Aia21 |
Adjuvant induced arthritis QTL 21 |
|
Induced |
IED |
13 |
10,688,543 |
55,688,543 |
RGD:2316974 |
RGD |
| Q |
Aia22 |
Adjuvant induced arthritis QTL 22 |
|
Induced |
IED |
13 |
1 |
23,584,369 |
RGD:2316974 |
RGD |
| Q |
Aia23 |
Adjuvant induced arthritis QTL 23 |
|
Induced |
IED |
13 |
1,084,268 |
33,188,609 |
RGD:2316974 |
RGD |
| Q |
Aia24 |
Adjuvant induced arthritis QTL 24 |
|
Induced |
IED |
15 |
58,412,001 |
80,362,100 |
RGD:2316974 |
RGD |
| Q |
Aia25 |
Adjuvant induced arthritis QTL 25 |
|
Induced |
IED |
17 |
59,104,944 |
71,569,891 |
RGD:2316974 |
RGD |
| Q |
Aia26 |
Adjuvant induced arthritis QTL 26 |
|
Induced |
IED |
17 |
49,069,974 |
94,069,974 |
RGD:2316974 |
RGD |
| Q |
Aia27 |
Adjuvant induced arthritis QTL 27 |
|
Induced |
IED |
20 |
3,039,759 |
37,383,914 |
RGD:2316974 |
RGD |
| Q |
Aia6 |
Adjuvant induced arthritis QTL 6 |
|
Induced |
IED |
10 |
70,229,781 |
115,229,781 |
RGD:2316974 |
RGD |
| Q |
Aia7 |
Adjuvant induced arthritis QTL 7 |
|
Induced |
IED |
10 |
41,317,054 |
86,317,054 |
RGD:2316974 |
RGD |
| Q |
Aia8 |
Adjuvant induced arthritis QTL 8 |
|
Induced |
IED |
13 |
10,688,543 |
55,688,543 |
RGD:2316974 |
RGD |
| Q |
Aia9 |
Adjuvant induced arthritis QTL 9 |
|
Induced |
IED |
13 |
1,084,268 |
33,188,609 |
RGD:2316974 |
RGD |
| Q |
Cia10 |
Collagen induced arthritis QTL 10 |
|
|
QTM |
2 |
188,136,088 |
233,136,088 |
RGD:61063 |
RGD |
| Q |
Cia13 |
Collagen induced arthritis QTL 13 |
|
|
QTM |
4 |
134,858,561 |
171,204,531 |
RGD:61067 |
RGD |
| Q |
Cia2 |
Collagen induced arthritis QTL 2 |
|
|
QTM |
1 |
33,153,323 |
78,153,323 |
RGD:61062 |
RGD |
| Q |
Cia27 |
Collagen induced arthritis QTL 27 |
|
|
IAGP |
10 |
95,695,048 |
111,406,914 |
RGD:61063 |
RGD |
| Q |
Cia3 |
Collagen induced arthritis QTL 3 |
|
|
QTM |
4 |
104,415,843 |
149,415,843 |
RGD:61062 |
RGD |
| Q |
Cia4 |
Collagen induced arthritis QTL 4 |
|
|
QTM |
7 |
62,224,456 |
66,202,126 |
RGD:61062 |
RGD |
| Q |
Cia5 |
Collagen induced arthritis QTL 5 |
|
|
QTM |
10 |
95,692,240 |
140,692,240 |
RGD:61062 |
RGD |
| Q |
Cia7 |
Collagen induced arthritis QTL 7 |
|
|
QTM |
2 |
59,700,886 |
146,659,672 |
RGD:61063 |
RGD |
| Q |
Cia9 |
Collagen induced arthritis QTL 9 |
|
|
QTM |
|
|
|
RGD:61063 |
RGD |
| Q |
Ciaa1 |
CIA Autoantibody QTL 1 |
|
|
QTM |
20 |
2,790,511 |
4,530,895 |
RGD:61066 |
RGD |
| Q |
Ciaa2 |
CIA Autoantibody QTL 2 |
|
|
QTM |
10 |
64,308,668 |
95,695,218 |
RGD:61066 |
RGD |
| Q |
Ciaa3 |
CIA Autoantibody QTL 3 |
|
|
QTM |
9 |
18,347,567 |
63,347,567 |
RGD:61066 |
RGD |
| Q |
Oia2 |
Oil induced arthritis QTL 2 |
|
|
QTM |
4 |
136,668,162 |
181,668,162 |
RGD:61087 |
RGD |
| Q |
Oia8 |
Oil induced arthritis QTL 8 |
|
|
QTM |
4 |
136,668,162 |
181,668,162 |
RGD:629560 |
RGD |
| Q |
Pia22 |
Pristane induced arthritis QTL 22 |
|
|
QTM |
12 |
530,865 |
45,530,865 |
RGD:629560 |
RGD |
| Q |
Pia40 |
Pristane induced arthritis QTL 40 |
|
Induced |
IED |
20 |
1,616,449 |
5,447,380 |
RGD:2306838 |
RGD |
| Q |
Pia42 |
Pristane induced arthritis QTL 42 |
|
Induced |
IED |
12 |
20,932,559 |
43,863,270 |
RGD:1600250 |
RGD |
| Q |
Pia5 |
Pristane induced arthritis QTL 5 |
|
|
QTM |
4 |
60,974,346 |
130,228,614 |
RGD:61089 |
RGD |
| S |
BBDR/WorN |
|
|
|
IED |
|
|
|
RGD:1578691 |
RGD |
| S |
DA.E3-(D4Wox49-D4Got136)/Rhd |
|
|
Resistance |
IED |
4 |
159,060,677 |
160,528,447 |
RGD:2324629 |
RGD |
| S |
DA.F344-(D10Rat204-D10Arb22)/Arb |
|
|
|
IED |
10 |
95,695,076 |
95,695,218 |
RGD:1599708 |
RGD |
| S |
DA.F344-(D10Rat24-D10Rat11)/Nsi |
|
|
|
IED |
10 |
69,160,380 |
106,310,957 |
RGD:1359065 |
RGD |
| S |
DA.F344-(D10Rat37-D10Arb22) |
|
|
|
IED |
10 |
24,006,429 |
24,006,612 |
RGD:1359065 |
RGD |
| S |
DA.F344-(D10Rat37-D10Arb9)/Nsi |
|
|
|
IED |
10 |
31,931,622 |
79,229,233 |
RGD:1599708 |
RGD |
| S |
DA.F344-(D10Rat37-D10Wox22)/Nsi |
|
|
|
IED |
10 |
31,931,622 |
100,633,982 |
RGD:1359065 |
RGD |
| S |
DA.F344-(D20Arb2-D20Arb8)/Arb |
|
|
|
IED |
20 |
2,790,511 |
2,811,567 |
RGD:629569 |
RGD |
| S |
DA.F344-(D4Arb30-D4Arb4)/Arb |
|
|
|
IED |
4 |
73,972,453 |
154,937,227 |
RGD:1599708 |
RGD |
| S |
DA.F344-(D7Arb5-D7Mit2)/Arb |
|
|
|
IED |
7 |
98,955,064 |
123,191,874 |
RGD:1599708 |
RGD |
| S |
DA.F344-(D8Arb15-D8Arb22)/Arb |
|
|
|
IED |
8 |
71,843,628 |
124,310,337 |
RGD:1599708 |
RGD |
| S |
E3.DA-(D12Wox5-D12Rat26)/Rhd |
|
|
Induced |
IED |
12 |
23,845,554 |
23,845,733 |
RGD:2306838 |
RGD |
| S |
F344.DA-(D20Arb2-D20Arb8)/Arb |
|
|
|
IED |
20 |
2,790,511 |
2,811,567 |
RGD:629569 |
RGD |
kidney inflammation
|
| Q |
Bp175 |
Blood pressure QTL 175 |
|
|
QTM |
2 |
222,939,299 |
256,217,383 |
RGD:727992 |
RGD |
| Q |
Rf12 |
Renal function QTL 12 |
|
|
QTM |
3 |
58,764,506 |
121,619,110 |
RGD:727992 |
RGD |
| Q |
Rf20 |
Renal function QTL 20 |
|
|
QTM |
11 |
29,744,366 |
62,045,696 |
RGD:727992 |
RGD |
| Q |
Rf9 |
Renal function QTL 9 |
|
|
QTM |
2 |
138,700,979 |
210,636,169 |
RGD:727992 |
RGD |
| S |
Hsd:SD |
Sprague Dawley |
|
Induced |
IED |
|
|
|
RGD:6903837 |
RGD |
liver inflammation
|
| S |
WF.LEW-RVFV |
|
|
|
TAS |
|
|
|
RGD:2292456 |
RGD |
| S |
WKAH.LEC-Atp7bhts/Tj |
|
|
|
TAS |
16 |
74,607,988 |
74,680,080 |
RGD:1302502 |
RGD |
pancreas inflammation
|
| G |
Tnf |
tumor necrosis factor |
|
|
IED |
20 |
3,661,000 |
3,663,618 |
RGD:1580295 |
RGD |
| Q |
Bw13 |
Body weight QTL 13 |
|
|
QTM |
X |
1 |
41,387,080 |
RGD:619682 |
RGD |
| Q |
Iddm11 |
Insulin dependent diabetes mellitus QTL 11 |
|
|
QTM |
4 |
56,920,444 |
78,042,833 |
RGD:61480 |
RGD |
| Q |
Iddm17 |
Insulin dependent diabetes mellitus QTL 17 |
|
|
QTM |
11 |
19,445,919 |
87,759,784 |
RGD:634732 |
RGD |
| Q |
Insul4 |
Insulin level QTL 4 |
|
|
QTM |
X |
134,157,190 |
160,699,376 |
RGD:619682 |
RGD |
| Q |
Panci1 |
Pancreas inflammation QTL 1 |
|
|
QTM |
7 |
123,574,930 |
134,614,033 |
RGD:619682 |
RGD |
| S |
F344.SDT-(D3Wox9-D3Arb20)/Kbe |
|
|
|
IED |
3 |
47,722,501 |
47,722,628 |
RGD:2298688 |
RGD |
periinsulitis
|
| S |
LEW.1WR1/WorBrm |
|
|
|
IED |
|
|
|
RGD:2313174 |
RGD |
reproductive system inflammation
|
| Q |
Eutr1 |
Estrogen induced uterine response QTL 1 |
|
|
IAGP |
5 |
1,220,773 |
79,863,911 |
RGD:1559292 |
RGD |
| Q |
Eutr2 |
Estrogen induced uterine response QTL 2 |
|
|
IAGP |
5 |
35,911,094 |
109,163,425 |
RGD:1559291 |
RGD |
small thymus
|
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
|
IAGP |
7 |
113,043,365 |
113,049,779 |
RGD:727991 |
RGD |
| Q |
Tsu1 |
Thymus enlargement suppressive QTL 1 |
|
|
QTM |
3 |
47,722,800 |
115,996,144 |
RGD:634729 |
RGD |
testis inflammation
|
| S |
LEW-Tg(HLA-B*2705m1,B2M)133-1Trg |
|
|
|
QTM |
|
|
|
RGD:731214 |
RGD |
thymus atrophy
|
| Q |
Esta4 |
Estrogen-induced thymic atrophy QTL 4 |
|
Induced |
IED |
3 |
44,551,252 |
149,496,698 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D10Mgh8-D10Rat4)/Shul |
|
|
Induced |
IED |
10 |
53,781,126 |
107,033,716 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D3Mgh16-D3Rat119)/Shul |
|
|
Induced |
IED |
3 |
6,373,335 |
52,643,538 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D3Rat130-D3Rat114)/Shul |
|
|
Induced |
IED |
3 |
44,551,252 |
149,496,698 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D6Rat80-D6Rat146)/Shul |
|
|
Induced |
IED |
6 |
16,302,145 |
16,302,283 |
RGD:2292503 |
RGD |
thymus hyperplasia
|
| Q |
Thym1 |
Thymus enlargement QTL 1 |
|
|
QTM |
1 |
141,471,946 |
186,471,946 |
RGD:70859 |
RGD |
| Q |
Thym2 |
Thymus enlargement QTL 2 |
|
|
QTM |
13 |
47,699,094 |
88,282,502 |
RGD:70859 |
RGD |
| S |
BUF/Mna |
|
|
|
QTM |
|
|
|
RGD:619599 |
RGD |
| S |
COP |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
W/Nhg |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
WAB |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
vascular inflammation
|
| S |
BN/Elh |
|
|
|
QTM |
|
|
|
RGD:619605 |
RGD |
vasculitis
|
| S |
ZDF |
Vancouver diabetic fatty Zucker |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
Term paths to the root
|